Safety profile of mRNA Covid-19 vaccines.
The evidence base remains contested, and headline studies often haven't been independently replicated at scale. @@no_510Counter
GLP-1 agonists: efficacy, cost-effectiveness, and equityArticle·bmj.comSystematic review of semaglutide and tirzepatide trials and a cost-effectiveness model for public reimbursement.Added by @lin3365Open link